GLP3-RT 20mg (Retatrutide, research designation LY3437943) is a high-purity synthetic investigational peptide supplied by Echo Peptides exclusively for in-vitro laboratory research. It is engineered as a single-molecule triple agonist that engages three distinct incretin and metabolic receptors — the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor.
As a reference compound, Retatrutide is of interest to researchers precisely because it consolidates three signaling axes into one structure. A fatty-acid conjugate is incorporated into the backbone to improve stability in research preparations, allowing investigators to study convergent incretin and glucagon pathways in a single, well-characterized model system rather than combining separate ligands.
Key research areas
- Multi-receptor metabolic and energy-expenditure models
- Glucose-homeostasis and appetite-regulation signaling pathways
- Lipid-metabolism and weight-management research paradigms
- Advanced incretin plus glucagon receptor cross-talk and co-agonism studies
Each lot is third-party tested for identity and purity, and a Certificate of Analysis is available for every batch. The peptide ships as a lyophilized powder in a sterile vial for reconstitution in bacteriostatic water or research buffers.
Specifications
- Compound: Retatrutide (LY3437943), triple GIP / GLP-1 / glucagon receptor agonist
- Amount: 20mg
- Form: Lyophilized white powder
- Modifications: Triple agonist with fatty-acid conjugate
- Solubility: Soluble in bacteriostatic water for research use
- Storage: Refrigerate at 2–8°C; long-term stability when lyophilized
This product is intended strictly for in-vitro laboratory research use only. It is not for human or veterinary use and not for diagnostic or therapeutic purposes.
